About AVEO Pharmaceuticals
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec.
|
|
|
11-50 employees
View all AVEO Pharmaceuticals employees
|
|
Medical Practices
|
|
(617) 588-1960
|
|
Cambridge, MA
|
|
2001
|
AVEO Pharmaceuticals Alternatives
Frequently Asked Questions about AVEO Pharmaceuticals
John Ryan is the CEO of AVEO Pharmaceuticals.
The decision makers in AVEO Pharmaceuticals are John Ryan, Steven Clark, Dennis Vargo, etc. Click to Find AVEO Pharmaceuticals decision makers emails.
AVEO Pharmaceuticals Staff Directory
Search AVEO Pharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
